348 related articles for article (PubMed ID: 20368009)
1. [Current status of prevention and management of radiation-induced xerostomia].
Ma DY; Qiu WL; Zhang CP
Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 Feb; 45(2):121-3. PubMed ID: 20368009
[No Abstract] [Full Text] [Related]
2. Pathophysiology and management of radiation-induced xerostomia.
Berk LB; Shivnani AT; Small W
J Support Oncol; 2005; 3(3):191-200. PubMed ID: 15915820
[TBL] [Abstract][Full Text] [Related]
3. In regard to Münter et Al. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without amifostine. (Int j radiat oncol biol phys 2007;67:651-659).
Messerschmidt GL; Oleka N
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1651-2; author reply 1652. PubMed ID: 18035221
[No Abstract] [Full Text] [Related]
4. Radiotherapy-induced salivary dysfunction.
Ship JA; Hu K
Semin Oncol; 2004 Dec; 31(6 Suppl 18):29-36. PubMed ID: 15726520
[TBL] [Abstract][Full Text] [Related]
5. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
de Castro G; Federico MH
Curr Opin Oncol; 2006 May; 18(3):266-70. PubMed ID: 16552239
[TBL] [Abstract][Full Text] [Related]
6. In regards to Münter et Al. (Int J Radiat Oncol Biol Phys 2007;67:651-659).
Samuels MA
Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):318; author reply 318-9. PubMed ID: 17707287
[No Abstract] [Full Text] [Related]
7. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
Thorstad WL; Chao KS; Haughey B
Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
[TBL] [Abstract][Full Text] [Related]
8. Management of xerostomia related to radiotherapy for head and neck cancer.
Kahn ST; Johnstone PA
Oncology (Williston Park); 2005 Dec; 19(14):1827-32; discussion 1832-4, 1837-9. PubMed ID: 16506635
[TBL] [Abstract][Full Text] [Related]
9. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine.
Münter MW; Hoffner S; Hof H; Herfarth KK; Haberkorn U; Rudat V; Huber P; Debus J; Karger CP
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):651-9. PubMed ID: 17175118
[TBL] [Abstract][Full Text] [Related]
10. Management of salivary hypofunction during and after radiotherapy.
Shiboski CH; Hodgson TA; Ship JA; Schiødt M
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103 Suppl():S66.e1-19. PubMed ID: 17379158
[TBL] [Abstract][Full Text] [Related]
11. The use of amifostine to prevent xerostomia in patients receiving radiation therapy.
Batcha M
Oncol Nurs Forum; 2000 May; 27(4):615-6. PubMed ID: 10833684
[No Abstract] [Full Text] [Related]
12. The prevention and treatment of radiotherapy - induced xerostomia.
Eisbruch A; Rhodus N; Rosenthal D; Murphy B; Rasch C; Sonis S; Scarantino C; Brizel D
Semin Radiat Oncol; 2003 Jul; 13(3):302-8. PubMed ID: 12903018
[TBL] [Abstract][Full Text] [Related]
13. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
Veerasarn V; Phromratanapongse P; Suntornpong N; Lorvidhaya V; Sukthomya V; Chitapanarux I; Tesavibul C; Swangsilpa T; Khorprasert C; Shotelersuk K; Kongthanarat Y; Panichevaluk A; Chiewvit S; Pusuwan P; Aekmahachai M; Ratchadara S; Sirilipoche S; Saengsuda Y
J Med Assoc Thai; 2006 Dec; 89(12):2056-67. PubMed ID: 17214057
[TBL] [Abstract][Full Text] [Related]
14. Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers.
Vissink A; Mitchell JB; Baum BJ; Limesand KH; Jensen SB; Fox PC; Elting LS; Langendijk JA; Coppes RP; Reyland ME
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):983-91. PubMed ID: 20970030
[TBL] [Abstract][Full Text] [Related]
15. New approaches to preventing xerostomia.
J Support Oncol; 2006 Feb; 4(2):87-8. PubMed ID: 16499130
[No Abstract] [Full Text] [Related]
16. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
[TBL] [Abstract][Full Text] [Related]
17. Salivary gland sparing in the treatment of head and neck cancer.
Scrimger R
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1437-48. PubMed ID: 21929317
[TBL] [Abstract][Full Text] [Related]
18. Reducing radiation-induced xerostomia with highly conformal radiotherapy techniques.
Eisbruch A
J Support Oncol; 2005; 3(3):201-2. PubMed ID: 15915821
[No Abstract] [Full Text] [Related]
19. The role of saliva in oral health: strategies for prevention and management of xerostomia.
Brosky ME
J Support Oncol; 2007 May; 5(5):215-25. PubMed ID: 17564151
[TBL] [Abstract][Full Text] [Related]
20. [Comments on five clinical trials concerning radiotherapy-induced mucositis in patients with head and neck neoplasms].
Noël G; Mazeron JJ
Cancer Radiother; 2001 Apr; 5(2):202-4. PubMed ID: 11355589
[No Abstract] [Full Text] [Related]
[Next] [New Search]
